Clinical Trial Update: CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CD19 CAR T-cell therapy for refractory systemic lupus erythematosus is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CD19 CAR-T cell therapy (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology | Conditions: Refractory Systemic Lupus Erythematosus | Phase 1 | Status: NOT_YET_RECRUITING